0000000001227927

AUTHOR

L. Surace

showing 3 related works from this author

Current practice of chronic hepatitis B treatment in Southern Italy

2012

Abstract Background Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. Methods A prospective study enrolling over a six month period (February–July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). Results Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (…

AdultMalemedicine.medical_specialtyHBsAgGuanineCirrhosisOrganophosphonatesPyrimidinonesNucleosides analoguesAntiviral AgentsPolyethylene GlycolsYoung AdultHepatitis B ChronicChronic hepatitisInterferonPegylated interferonInternal medicineHBVInternal MedicinemedicineHumansHepatitis B e AntigensPractice Patterns Physicians'TenofovirProspective cohort studyAgedAged 80 and overTelbivudinebusiness.industryAdenineAge FactorsInterferon-alphaNucleosidesMiddle AgedHBV; Interferon; Nucleosides analogues; Nucleotides analoguesNucleotides analoguesmedicine.diseaseRecombinant ProteinsItalyLamivudineCurrent practiceImmunologyInterferonFemalePreviously treatedbusinessThymidinemedicine.drugEuropean Journal of Internal Medicine
researchProduct

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct